Avalo Therapeutics, Inc.
NASDAQAvalo Therapeutics heads into the back half of June with a striking split: short sellers hold a third of the float while every analyst covering the stock rates it a Buy. The short positioning is the most immediate tension. At 35.5% of the free float, short interest has climbed 28% over the past month — the bulk of that build appears concentrated in the second half of May, when…
AVTX cost to borrow surges 167% in one week to 1.54%, as short interest climbs to 30.7% of float ahead of earnings Friday.
Snapshot as of 22 Jun 2026
Avalo Therapeutics heads into the back half of June with a striking split: short sellers hold a third of the float while every analyst covering the stock rates it a Buy. The short positioning is the most immediate…
Five AVTX executives sold shares on the same day. The stock had just surged 57% in a week. The lending market heard it too — availability has swung from near-zero to wide open. On May 6, five senior Avalo Therapeutics…
Avalo Therapeutics lit up screens this week. Positive Phase 2 LOTUS trial data for AVTX-009 — its lead IL-1β inhibitor targeting hidradenitis suppurativa — sent the stock up 18% on Tuesday and 26% on the week to…
Avalo Therapeutics reports on May 8 carrying one of the most contested short-interest profiles in small-cap biotech. The bear trade is substantial. Short interest has climbed to 30.7% of the free float — up 29% over…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AVTX — free to start on ORTEX.
Sign up for free →Open AVTX on ORTEX